MEDI9447 Alone and in Combination with MEDI4736 in Adult Subjects with Select Advanced Solid Tumors

Exclusion Criteria

• *Prior treatment with tumor necrosis factor receptor superfamily agonists including OX40, CD27, CD137 (4-1BB), CD357 (GITR). One cohort also excludes anti CTLA-4, anti PDL-1 and anti PDL-1.
• *Subjects who have received prior therapy with regimens containing CTLA-4, PD-L1, or PD-1 antagonists may be permitted to enroll under certain conditions
• *Cardiac or peripheral vascular disease meeting any of the following criteria:
• ◦Past history of myocardial infarction in the prior 12 months
• ◦Past history of stroke or transient ischemic attack requiring medical therapy
• ◦Congestive heart failure ≥ Class 3 based on New York Heart Association Functional Classification
• *Grade 3 or greater edema (eg, peripheral, pulmonary)
• *History of Grade 3 or greater thromboembolic events in the prior 12 months
• *Subjects with active tuberculosis are ineligible. In settings where there is clinical or radiographic evidence of tuberculosis, active disease must be ruled out
• *Active or prior documented autoimmune or inflammatory disorders
• *Untreated central nervous system (CNS) metastatic disease
• *Known positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or C
• *Other invasive malignancy within 2 years except for noninvasive malignancies such as cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, ductal carcinoma in situ of the breast that has been surgically cured
• *Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, active peptic ulcer disease or gastritis, uncontrolled hypertension, uncontrolled diabetes, or psychiatric illness/social situations that would limit compliance with study requirement